Historical record - last NADAC effective date: 1/1/2017
Product Information
ACTEMRA 162 MG/0.9 ML SYRINGE is a brand product labeled by Genentech, Inc., priced at $1001.1205 per ML under NDC 50242013801. Its NADAC has been published 135 times since Jun 18, 2014.
Strength
162 mg/.9mL
Manufacturer
Genentech, Inc.NDC
50242013801
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
1/1/2017
Active Ingredients
TOCILIZUMABApproval Type
Biologic (BLA)
FDA Application
BLA125472On Market Since
10/21/2013
Pharmacological Classes
Price Statistics
The NADAC for ACTEMRA 162 MG/0.9 ML SYRINGE has been published 135 times since Jun 18, 2014, and over the history we have for it it has risen 46.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1001.1205 per ML |
|---|---|
| All-time high | $1001.1205 (Jan 11, 2017) |
| All-time low | $683.0533 (Jun 18, 2014) |
| Median price | $827.2625 |
| Average price | $823.2715 |
| Largest weekly change | +8.0% (Jul 8, 2015) |
| Weeks tracked | 135 |
| Tracking since | Jun 18, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+46.6%
Last surveyed Jan 11, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Genentech, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tocilizumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-6 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACTEMRA 162 MG/0.9 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for ACTEMRA 162 MG/0.9 ML SYRINGE, manufactured by Genentech, Inc., is $1001.1205 per ML (NDC 50242013801), effective Jan 11, 2017.
How has the price of ACTEMRA 162 MG/0.9 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for ACTEMRA 162 MG/0.9 ML SYRINGE has risen 46.6%. It has been tracked across 135 weekly CMS publications since Jun 18, 2014.
What are the highest and lowest recorded NADAC prices for ACTEMRA 162 MG/0.9 ML SYRINGE?
Since Jun 18, 2014, the NADAC for ACTEMRA 162 MG/0.9 ML SYRINGE has ranged from a low of $683.0533 (Jun 18, 2014) to a high of $1001.1205 (Jan 11, 2017), with a median of $827.2625 per ML.
Are there cheaper alternatives to ACTEMRA 162 MG/0.9 ML SYRINGE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ACTEMRA 162 MG/0.9 ML SYRINGE in a comparable dosage form, but none are currently priced below it.
Who manufactures ACTEMRA 162 MG/0.9 ML SYRINGE?
ACTEMRA 162 MG/0.9 ML SYRINGE (NDC 50242013801) is labeled by Genentech, Inc., and CMS classifies it as a brand product.